A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function

NCT07694843 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants
Participants With Mild Hepatic Impairment
Participants With Moderate Hepatic Impairment

Interventions

DRUG: ammoxetine hydrochloride enteric-coated tablets

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.